Sepracor, Inc. Release: Results of Studies of Eslicarbazepine Acetate for the Treatment of Epilepsy to Be Presented at American Epilepsy Society Annual Meeting

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced that clinical study data for eslicarbazepine acetate in the treatment of epilepsy will be presented at the 62nd annual meeting of the American Epilepsy Society in Seattle on December 8, 2008. The posters will be presented in the Washington State Convention Center during the morning poster sessions.